



CryoLife Appoints David M. Fronk Vice President, Regulatory Affairs and Quality Assurance

April 14, 2005

ATLANTA, April 14 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials and biosurgical device company, announced today that David M. Fronk has been appointed to the position of Vice President, Regulatory Affairs and Quality Assurance. Mr. Fronk was formerly the Vice President of Clinical Research at CryoLife, a position he assumed in 1998. Since joining the Company in 1992, Mr. Fronk has held several positions in the Clinical Research Department. Mr. Fronk will continue to report to Steven G. Anderson, President and CEO at CryoLife, Inc. in his new position and replaces Dr. Thomas J. Lynch, who has accepted a position with another company.

Prior to joining CryoLife, Mr. Fronk worked at Baxter Healthcare Corporation and Zimmer, Inc. Mr. Fronk holds a B.S., Mechanical Engineering, and an M.S., Biomedical Engineering, from The Ohio State University.

"Dave has worked closely with the FDA on our tissue processing improvements, several clinical projects, and various regulatory matters. He will bring his expertise and experience to his new role, leading our Regulatory Affairs and Quality Assurance group," said Steven G. Anderson, President and CEO, CryoLife, Inc. Mr. Anderson also noted, "We wish Dr. Lynch success in his future endeavors and thank him for his many contributions to the Company."

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels, CE marked in the European Community, approved in Canada for use in soft tissue repair, and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SG Model #100 vascular graft, which is CE marked for distribution within the European Community.

Contact: Joseph T. Schepers

Vice President, Corporate Communications
(770) 419-3355

SOURCE CryoLife, Inc.